CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Bevacizumab 1.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00729846
NCT00729846Phase 2Completed
CompareCT.gov

Combination Bevacizumab and Verteporfin (Standard and Reduced Fluence)in the Treatment of Neovascular Age-Related Macular Degeneration

California Retina Consultants·interventional·Posted Aug 8, 2008·Updated Apr 20, 2016

In Brief

A Phase 2 clinical trial evaluating Bevacizumab, verteporfin photodynamic therapy reduced fluence, and 1 other intervention for Age Related Macular Degeneration and 2 related conditions. Completed, enrolled 22 participants across 2 sites.

Detailed Summary

To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degeneration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration, Choroidal Neovascularization, Macular Edema
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2008
Enrollment StartMay 1, 2006
Primary CompletionAug 1, 2008
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.9 years ago

Interventions

Bevacizumabdrug

Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.

verteporfin photodynamic therapy reduced fluencedevice

Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].

verteporfin photodynamic therapy standardfluencedevice

Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].